肢端肥大症

Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355:2558-2573.

• 摘要

Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol. 2005;153:737-740.

• 全文
• 摘要

Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89-95.

• 全文
• 摘要

Strasburger CJ, Buchfelder M, Droste M, et al; German Pegvisomant Investigators. Experience from the German pegvisomant observational study. Horm Res. 2007;68:70-73.

• 摘要

Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102-152.

• 全文
• 摘要

1.  Melmed S. Medical progress: acromegaly. N Engl J Med. 2006;355:2558-2573.

• 摘要

2.  Daly AF, Rixhon M, Adam C, et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J Clin Endocrinol Metab. 2006;91:4769-4775.

• 摘要

3.  Holdaway IM, Rajasoorya C. Epidemiology of acromegaly. Pituitary. 1999;2:29-41.

• 摘要

4.  Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004;101:613-619.

• 全文
• 摘要

5.  Trivellin G, Daly AF, Faucz FR, et al. Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med. 2014;371:2363-2374.

• 全文
• 摘要

6.  Horvath A, Stratakis CA. Clinical and molecular genetics of acromegaly: MEN-1, Carney complex, McCune-Albright syndrome, familial acromegaly and genetic defects in sporadic tumors. Rev Endocr Metab Disord. 2008;9:1-11.

• 摘要

7.  Melmed S. Update in pituitary disease. J Clin Endocrinol Metab. 2008;93:331-338.

• 全文
• 摘要

8.  Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000;85:526-529.

• 全文
• 摘要

9.  Cheng V, Faiman C, Kennedy L, et al. Pregnancy and acromegaly: a review. Pituitary. 2012;15:59-63.

• 摘要

10.  Ribeiro-Oliveira A Jr, Faje AT, Barkan AL. Limited utility of oral glucose tolerance test in biochemically active acromegaly. Eur J Endocrinol. 2011;164:17-22.

• 全文
• 摘要

11.  Freda PU, Beckers AM, Katznelson L, et al; Endocrine Society. Pituitary incidentaloma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:894-904.

• 全文
• 摘要

12.  Scangas GA, Laws ER Jr. Pituitary incidentalomas. Pituitary. 2014;17:486-491.

• 摘要

13.  Cordero RA, Barkan AL. Current diagnosis of acromegaly. Rev Endocr Metab Disord. 2008;9:13-19.

• 摘要

14.  Katznelson L, Atkinson JL, Cook DM, at al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly - 2011 update. Endocr Pract. 2011;17(Suppl 4):1-44.

• 全文
• 摘要

15.  Giustina A, Chanson P, Bronstein MD, et al; Acromegaly Consensus Group. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab. 2010;95:3141-3148.

• 全文
• 摘要

16.  Hardy J. Transphenoidal microsurgery of the normal and pathological pituitary. Clin Neurosurg. 1969;16:185-217.

• 摘要

17.  Al-Shraim M, Asa SL. The 2004 World Health Organization classification of pituitary tumors: what is new? Acta Neuropathol. 2006;111:1-7.

• 摘要

18.  Melmed S, Casanueva F, Cavagnini F, et al. Consensus statement: medical management of acromegaly. Eur J Endocrinol. 2005;153:737-740.

• 全文
• 摘要

19.  Orme SM, McNally RJ, Cartwright RA, et al. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab. 1998;83:2730-2734.

• 全文
• 摘要

20.  Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008;159:89-95.

• 全文
• 摘要

21.  Laws ER. Surgery for acromegaly: evolution of the techniques and outcomes. Rev Endocr Metab Disord. 2008;9:67-70.

• 摘要

22.  Vallette S, Serri O. Octreotide LAR for the treatment of acromegaly. Expert Opin Drug Metab Toxicol. 2008;4:783-793.

• 摘要

23.  Colao A, Pivonello R, Rosato F, et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol (Oxf). 2006;64:342-351.

• 摘要

24.  Cozzi R, Montini M, Attanasio R, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91:1397-1403.

• 全文
• 摘要

25.  Giustina A, Mazziotti G, Torri V, et al. Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One. 2012;7:e36411.

• 全文
• 摘要

26.  Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93:2957-2968.

• 摘要

27.  Mazziotti G, Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary. 2010;13:60-67.

• 摘要

28.  Abs R, Verhelst J, Maiter D, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83:374-378.

• 全文
• 摘要

29.  Sandret L, Maison P, Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2011;96:1327-1335.

• 全文
• 摘要

30.  Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000;342:1171-1177.

• 全文
• 摘要

31.  Strasburger CJ, Buchfelder M, Droste M, et al; German Pegvisomant Investigators. Experience from the German pegvisomant observational study. Horm Res. 2007;68:70-73.

• 摘要

32.  Roelfsema F, Biermasz NR, Pereira AM, et al. The role of pegvisomant in the treatment of acromegaly. Expert Opin Biol Ther. 2008;8:691-704.

• 摘要

33.  Barkan AL, Halasz I, Dornfeld KJ, et al. Pituitary irradiation is ineffective in normalizing plasma insulin-like growth factor I in patients with acromegaly. J Clin Endocrinol Metab. 1997;82:3187-3191.

• 全文
• 摘要

34.  Minniti G, Jaffrain-Rea ML, Osti M, et al. The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 2005;62:210-216.

• 摘要

35.  Castinetti F, Morange I, Dufour H, et al. Radiotherapy and radiosurgery in acromegaly. Pituitary. 2009;12:3-10.

• 摘要

36.  Stone JC, Clark J, Cuneo R, et al. Estrogen and selective estrogen receptor modulators (SERMs) for the treatment of acromegaly: a meta-analysis of published observational studies. Pituitary. 2014;17:284-295.

• 摘要

37.  Balili I, Barkan A. Tamoxifen as a therapeutic agent in acromegaly. Pituitary. 2014;17:500-504.

• 摘要

38.  Duarte FH, Jallad RS, Bronstein MD. Clomiphene citrate for treatment of acromegaly not controlled by conventional therapies. J Clin Endocrinol Metab. 2015;100:1863-1869.

• 摘要

39.  Feenstra J, de Herder WW, ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005;365:1644-1646.

• 摘要

40.  Moore DJ, Adi Y, Connock MJ, et al. Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord. 2009;9:20.

• 全文
• 摘要

41.  Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99:791-799.

• 全文
• 摘要

42.  Samson SL. Pasireotide in acromegaly: an overview of current mechanistic and clinical data. Neuroendocrinology. 2015;102:8-17.

• 全文
• 摘要

43.  Pita-Gutierrez F, Pertega-Diaz S, Pita-Fernandez S, et al. Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One. 2013;8:e61523.

• 全文
• 摘要

44.  Zhang L, Wu X, Yan Y, et al. Preoperative somatostatin analogs treatment in acromegalic patients with macroadenomas. A meta-analysis. Brain Dev. 2015;37:181-190.

• 摘要

45.  Shen M, Shou X, Wang Y, et al. Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study. Endocr J. 2010;57:1035-1044.

• 全文
• 摘要

46.  Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25:102-152.

• 全文
• 摘要

47.  Maison P, Tropeano AI, Macquin-Mavier I, et al. Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2007;92:1743-1747.

• 全文
• 摘要

48.  Herrmann BL, Wessendorf TE, Ajaj W, et al. Effects of octreotide on sleep apnoea and tongue volume (magnetic resonance imaging) in patients with acromegaly. Eur J Endocrinol. 2004;151:309-315.

• 全文
• 摘要

49.  Biermasz NR, Pereira AM, Smit JW, et al. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab. 2005;90:2731-2739.

• 全文
• 摘要

50.  Renehan AG, Shalet SM. Acromegaly and colorectal cancer: risk assessment should be based on population-based studies. J Clin Endocrinol Metab. 2002;87:1909.

• 全文
• 摘要

51.  Melmed S, Casanueva FF, Cavagnini F, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab. 2002;87:4054-4058.

• 全文
• 摘要